We were proud to showcase our preclinical progress at the 2025 International HBV Meeting hosted by the Hepatitis B Foundation this year in Berlin! Our team delivered six presentations demonstrating our continued innovation in liver and viral diseases. Key updates included: • Preclinical data showing our lead chronic #HBV therapeutic candidate reduces HBV cccDNA • Expansion of our pipeline to include a discovery stage ASO program for the treatment of hepatitis delta virus (HDV).
Congratulations. This is truly great progress!
Co-founder & VP, Head of Medicinal Chemistry at Onco3R Therapeutics
1moCongrats on your presentations! Nice to see great results delivered by such happy scientists🙂